Designer Receptor Exclusively Activated by Designer Drug (DREADD)-Mediated Activation of the Periaqueductal Gray Restores Nociceptive Descending Inhibition After Traumatic Brain Injury in Rats
- 17 July 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Neurotrauma
- Vol. 41 (13-14) , e1761-e1779
Abstract
Traumatic brain injury (TBI) patients frequently experience chronic pain that can enhance their suffering and significantly impair rehabilitative efforts. Clinical studies suggest that damage to the periaqueductal gray matter (PAG) following TBI, a principal center involved in endogenous pain control, may underlie the development of chronic pain. We hypothesized that TBI would diminish the usual pain control functions of the PAG, but that directly stimulating this center using a chemogenetic approach would restore descending pain modulation. We used a well-characterized lateral fluid percussion model (1.3 ± 0.1 atm) of TBI in male rats ( n = 271) and measured hindpaw mechanical nociceptive withdrawal thresholds using von Frey filaments. To investigate the role of the PAG in pain both before and after TBI, we activated the neurons of the PAG using a Designer Receptor Exclusively Activated by Designer Drug (DREADD) viral construct. Immunohistochemical analysis of brain tissue was used to assess the location and confirm the appropriate expression of the viral constructs in the PAG. Activation of the PAG DREADD using clozapine N-oxide (CNO) caused hindpaw analgesia that could be blocked using opioid receptor antagonist, naloxone, in uninjured but not TBI rats. Due to the importance of descending serotonergic signaling in modulating nociception, we ablated spinal serotonin signaling using 5,7-DHT. This treatment strongly reduced CNO-mediated anti-nociceptive effects in TBI but not uninjured rats. To define the serotonergic receptor(s) required for the CNO-stimulated effects in TBI rats, we administered 5-HT 7 (SB-269970) and 5-HT 1A (WAY-100635) receptor antagonists but observed no effects. The selective 5-HT 2A receptor antagonist ketanserin, however, blocked CNO's effects in the DREADD expressing TBI but not DREADD expressing sham TBI animals. Blockade of alpha-1 adrenergic receptors with prazosin also had no effect after TBI. Descending pain control originating in the PAG is mediated through opioid receptors in uninjured rats. TBI, however, fundamentally alters the descending nociceptive control circuitry such that serotonergic influences predominate, and those are mediated by the 5-HT 2A receptor. These results provide further evidence that the PAG is a key target for anti-nociception after TBI.Keywords
This publication has 88 references indexed in Scilit:
- Differential mediation of descending pain facilitation and inhibition by spinal 5HT-3 and 5HT-7 receptorsBrain Research, 2009
- Descending control of nociception: Specificity, recruitment and plasticityBrain Research Reviews, 2009
- Prevalence of Chronic Pain After Traumatic Brain InjuryJAMA, 2008
- Descending control of persistent pain: inhibitory or facilitatory?Brain Research Reviews, 2004
- Columnar organization in the midbrain periaqueductal gray: modules for emotional expression?Trends in Neurosciences, 1994
- Stimulation-produced descending inhibition from the periaqueductal gray and nucleus raphe magnus in the rat: mediation by spinal monoamines but not opioidsPain, 1987
- II. Examination of spinal monoamine receptors through which brainstem opiate-sensitive systems act in the ratBrain Research, 1986
- Role of the nucleus raphe magnus in opiate analgesia as studied by the microinjection technique in the ratBrain Research, 1979
- Evaluation of the periaqueductal central gray (PAG) as a morphine-specific locus of action and examination of morphine-induced and stimulation-produced analgesia at coincident PAG lociBrain Research, 1977
- Pain reduction by focal electrical stimulation of the brain: An anatomical and behavioral analysisBrain Research, 1974